Comparative Pharmacology
Head-to-head clinical analysis: DILAUDID HP versus TALWIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILAUDID HP versus TALWIN.
DILAUDID-HP vs TALWIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydromorphone is a full mu-opioid receptor agonist with high affinity for mu-opioid receptors, producing analgesia, euphoria, and sedation. It also binds to kappa and delta opioid receptors with lower affinity.
Agonist at kappa-opioid receptors and antagonist at mu-opioid receptors; produces analgesia through spinal and supraspinal mechanisms.
Initial dose: 0.2-0.6 mg IV/IM/SC every 2-4 hours as needed; usual adult dose: 0.2-0.4 mg IV/IM/SC. Oral: 1-2 mg every 3-6 hours. Dose titration based on pain severity.
50 mg orally every 3-4 hours as needed; maximum 600 mg/day. For severe pain, 30 mg intramuscularly or subcutaneously every 3-4 hours; maximum 360 mg/day parenterally.
None Documented
None Documented
Terminal elimination half-life: 2.3–4 hours. In clinical context, consistent with dosing interval of 4–6 hours for immediate-release formulations; prolonged in hepatic or renal impairment.
2-3 hours in adults; prolonged to 4-6 hours in hepatic impairment; clinical context: short half-life necessitates frequent dosing for chronic pain
Renal: predominantly as hydromorphone-3-glucuronide (H3G), unchanged hydromorphone (<6%), and other metabolites. Biliary/fecal: minimal.
Renal: 60-70% as unchanged drug and metabolites (pentazocine and its glucuronide conjugate); biliary/fecal: 20-30%
Category C
Category C
Opioid Analgesic
Opioid Analgesic